Analysis of risk factors for disease progression after salvage radiation therapy with androgen deprivation therapy in prostate cancer patients who have prostate-specific antigen persistence after radical prostatectomy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Advanced prostate cancer progression after salvage radiation therapy (SRT) with androgen deprivation therapy (ADT) is linked to pathological T stage (pT3b) and post-prostatectomy PSA levels (≥2.04 ng/mL). These factors predict recurrence in patients with persistent PSA after radical prostatectomy.
Area Of Science
- Urology
- Oncology
- Radiation Oncology
Background
- Prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) indicates residual disease.
- Salvage radiation therapy (SRT) combined with androgen deprivation therapy (ADT) is a treatment option for PSA persistence.
- Identifying risk factors for disease progression after SRT is crucial for patient management.
Purpose Of The Study
- To identify risk factors for disease progression in patients treated with SRT and ADT for PSA persistence post-RP.
- To evaluate the impact of pre-treatment characteristics on outcomes.
Main Methods
- Retrospective analysis of 57 patients receiving SRT with ADT for PSA persistence post-RP (2013-2019).
- Disease progression defined as biochemical or clinical recurrence.
- Analysis of potential predictors including age, pre-RP PSA, Gleason score, pathologic stage, lymph node dissection, surgical margins, and early post-RP PSA.
- Kaplan-Meier and Cox regression models used for statistical analysis.
Main Results
- Seventeen patients experienced disease progression during a median follow-up of 38 months.
- Pathologic T stage (pT3b) and PSA level at 6-8 weeks post-RP (≥2.04 ng/mL) were significant predictors of disease progression.
- Disease progression-free survival rates were notably lower for pT3b stage (46.7%) and PSA ≥2.04 ng/mL (18.4%) compared to their respective counterparts.
Conclusions
- Pathological T stage (pT3b) and early post-RP PSA levels (≥2.04 ng/mL) are independent risk factors for disease progression.
- These findings aid in risk stratification and personalized treatment strategies for patients with PSA persistence post-RP undergoing SRT with ADT.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Survival Times Are Positively Skewed
Survival times often exhibit positive skewness, unlike the normal distribution assumed...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...